On a previous study conducted in Brazil. The MMR vaccine from 2 different producers had a mumps seroconversion much lower (71%) than the expected 95%, according to the package insert. This could indicate that a substantial proportion of children was not protected after MMR dose.

Assess the immunoresponse for measles, mumps and rubella after vaccination with MMR in children 12-23 months and 29 days old, in the routine of National Immunization Program (NIP) in health units in the city of Rio de Janeiro.

To evaluate the immunoresponse after revaccination of children who did not seroconvert for any of the three components of the vaccine.

Biospecimen Retention: Samples With DNA

Whole blood

Enrollment:

150

Study Start Date:

May 2008

Study Completion Date:

August 2009

Primary Completion Date:

March 2009 (Final data collection date for primary outcome measure)

Intervention Details:

Biological: MMR (Mumps, Measles and Rubella)

MMR (Mumps, Measles and Rubella)

Detailed Description:

Given the above and considering: (1) future clinical study with the MMR vaccine produced entirely in Bio-Manguinhos/Fiocruz from technology transfer from GlaxoSmithKline (GSK), (2) the importance to the National Immunization Program (NIP) to provide the population a MMR vaccine to ensure high protection against mumps, similar to what occurs with measles and rubella components, it was considered essential to conduct a preliminary immunogenicity assessment of the MMR vaccine produced by BioManguinhos.

Eligibility

Ages Eligible for Study:

12 Months to 24 Months (Child)

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

Yes

Sampling Method:

Probability Sample

Study Population

Children 12-23 months and 29 days old, in the routine of PNI in health units in the city of Rio de Janeiro.

Criteria

Inclusion Criteria:

Children of both sexes;

Age between 12 months to 23 months and 29 days;

Child in good health, with no significant past medical history;

Have completed blood sampling before vaccination;

Have not been vaccinated with MMR.

Agreement by parents/tutors with the child's participation in the study and signing of the Informed Consent Form (ICF);

Parents/Tutors provide name, address, telephone number and other information for the contact if necessary;

Parents/Tutors able to understand the risks of the experiment, although minimal;

Parents/Tutors able to understand and sign the informed consent form.

Availability of return for collecting post-vaccination samples.

Exclusion criteria:

Children with a history of measles, rubella and / or mumps.

Having received MMR vaccine previously, as documented in vaccination card.

Having received a transfusion of blood or blood products, including immunoglobulins, within last 12 months.

Skin lesions at sites of venipuncture.

Child subject to abnormal bleeding after injections.

Use within 6 months of corticosteroids (excluding topical or aerosol) and immunosuppressants.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01874457